Amedisys Gestione

Gestione criteri di controllo 1/4

Amedisys Il CEO è Richard Ashworth, nominato in Apr2023, e ha un mandato di 1.58 anni. la retribuzione annua totale è $ 16.97M, composta da 4.1% di stipendio e 95.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.088% delle azioni della società, per un valore di € 2.49M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.6 anni e 5 anni.

Informazioni chiave

Richard Ashworth

Amministratore delegato

US$17.0m

Compenso totale

Percentuale dello stipendio del CEO	4.1%
Mandato del CEO	1.6yrs
Proprietà del CEO	0.09%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Richard Ashworth rispetto agli utili di Amedisys?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$83m
Jun 30 2024	n/a	n/a	US$92m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$17m	US$692k	-US$10m

Compensazione vs Mercato: La retribuzione totale di Richard ($USD 16.97M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.90M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Richard con le performance aziendali.

AMMINISTRATORE DELEGATO

Richard Ashworth (49 yo)

1.6yrs

Mandato

US$16,974,025

Compensazione

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Ashworth	President	1.6yrs	US$16.97m	0.088% € 2.5m
Scott Ginn	Executive VP	7.1yrs	US$4.45m	0.077% € 2.2m
Denise Bohnert	Chief Compliance Officer	5.2yrs	US$1.28m	Nessun dato
Nick Muscato	Chief Strategy Officer	no data	US$1.37m	0.0065% € 184.3k
Allyson Guidroz	Chief Accounting Officer & Principal Accounting Officer	1.3yrs	Nessun dato	0.0097% € 274.2k
Pete Hartley	CTO & Senior VP of Business Operations Systems	no data	Nessun dato	Nessun dato
Keith Blanchard	Acting Chief Information Officer	less than a year	Nessun dato	Nessun dato
Jennifer Griffin	Senior VP	2.1yrs	Nessun dato	0.024% € 670.3k
Kendra Kimmons	VP of Marketing & Communications & Media Relations	no data	Nessun dato	Nessun dato
Caitlin Franklin	Acting Chief People Officer	less than a year	Nessun dato	Nessun dato
Francis Mayer	Senior Vice President of Development	no data	Nessun dato	Nessun dato

1.6yrs

Durata media

47.5yo

Età media

Gestione esperta: Il team dirigenziale di ADY non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Ashworth	President	1.6yrs	US$16.97m	0.088% € 2.5m
Paul Kusserow	Chairman	9.9yrs	US$4.00m	1.33% € 37.8m
Bruce Perkins	Independent Director	9.6yrs	US$267.62k	0.063% € 1.8m
Vickie Capps	Independent Director	5yrs	US$277.62k	0.020% € 558.3k
Molly Coye	Independent Director	5yrs	US$267.62k	0.017% € 471.8k
Julie Klapstein	Lead Independent DIrector	8.6yrs	US$282.62k	0.039% € 1.1m
Jeffrey Rideout	Independent Director	8.6yrs	US$267.62k	0.018% € 516.6k
Teresa Kline	Independent Director	5yrs	US$272.62k	0.020% € 558.3k
Ivanetta Samuels	Independent Director	3.9yrs	US$252.62k	0.013% € 366.4k

5.0yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ADY sono considerati esperti (durata media dell'incarico 5 anni).

Amedisys Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: US$0.52 (vs US$0.80 in 3Q 2023)

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Second quarter 2024 earnings released: EPS: US$0.99 (vs US$2.46 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.44 (vs US$0.78 in 1Q 2023)

Full year 2023 earnings released: US$0.30 loss per share (vs US$3.65 profit in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.79 in 3Q 2022)

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 18%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

First quarter 2023 earnings released: EPS: US$0.78 (vs US$0.97 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.65 (vs US$6.41 in FY 2021)

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Now 21% undervalued after recent price drop

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.79 (vs US$1.38 in 3Q 2021)

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

First quarter 2022 earnings released: EPS: US$0.97 (vs US$1.52 in 1Q 2021)

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently bought €125k worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Independent Director recently sold €1.8m worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

President & COO recently sold €64k worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold €420k worth of stock

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

New 90-day low: €195

Independent Director recently bought €215k worth of stock

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Revenue misses expectations

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

New 90-day high: €254

New 90-day high: €242

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

New 90-day high: €236

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

New 90-day high: €228

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day high: €214

New 90-day high - €204